Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIG 2-98: Adjuvant Docetaxel in Node-Positive Breast Cancer
NCT00174655Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 1998
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (4 arms), sponsored by Sanofi. Primary endpoint: Disease-Free Survival at 5 years. Started Jun 1998; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00174655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174655.